Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia

Current Medical Research and Opinion

Volumn 32, Issue 10, 2016, Pages 1719-1725

  Pedersen Bjergaard, Ulrik ^a,b   Kristensen, Peter Lommer ^a   Nørgaard, Kirsten ^c   Perrild, Hans ^d   Jensen, Tonny ^e   Thorsteinsson, Birger ^a,b   Nikolajsen, Annie ^f   Tarnow, Lise ^a,g,h  

^a HILLERØD HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e University of Copenhagen   (Denmark)

^f NOVO NORDISK A S   (Denmark)

^g AARHUS UNIVERSITY   (Denmark)

^h STENO DIABETES CENTER   (Denmark)

Author keywords

Cost analysis; Diabetes complications; Hypoglycemia; Insulin; Type 1 diabetes mellitus

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; ISOPHANE INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SENSITIVITY ANALYSIS;

EID: 84978700559     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2016.1205006     Document Type: Article

References (31)

1. E.R.Seaquist, J.Anderson, B.Childs,. Hypoglycemia and diabetes:a report of a workgroup of the American Diabetes Association and the Endocrine Society. J Clin Endocrinol Metab 2013;98:1845-59
2. U.Pedersen-Bjergaard, S.Pramming, S.R.Heller,. Severe hypoglycaemia in 1076 adult patients with type 1 diabetes:influence of risk markers and selection. Diabetes Metab Res Rev 2004;20:479-86
3. P.L.Kristensen, L.S.Hansen, M.J.Jespersen,. Insulin analogues and severe hypoglycaemia in type 1 diabetes. Diabetes Res Clin Pract 2012;96:17-23
4. P.E.Cryer Death during intensive glycemic therapy of diabetes:mechanisms and implications. Am J Med 2011;124:993-6
5. A.E.Gold, I.J.Deary, B.M.Frier Hypoglycaemia and non-cognitive aspects of psychological function in insulindependent (type 1) diabetes mellitus (IDDM). Diabet Med 1997;14:111-18
6. M.W.Strachan, I.J.Deary, F.M.Ewing, B.M.Frier Recovery of cognitive function and mood after severe hypoglycemia in adults with insulin-treated diabetes. Diabetes Care 2000;23:305-12
7. R.E.Davis, M.Morrissey, J.R.Peters,. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005;21:1477-83
8. S.Barendse, H.Singh, B.M.Frier, J.Speight The impact of hypoglycaemia on quality of life and related patient-reported outcomes in type 2 diabetes:a narrative review. Diabet Med 2012;29:293-302
9. I.B.Hirsch Insulin analogues. N Engl J Med 2005;352:174-83
10. A.Siebenhofer, J.Plank, A.Berghold,. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006;2:CD003287
11. S.R.Singh, F.Ahmad, A.Lal,. Efficacy and safety of insulin analogues for the management of diabetes mellitus:a meta-analysis. CMAJ 2009;180:385-97
12. U.Pedersen-Bjergaard, P.L.Kristensen, H.Beck-Nielsen,. Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial):a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes Endocrinol 2014;2:553-61
13. P.L.Kristensen, U.Pedersen-Bjergaard, H.Beck-Nielsen,. A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna Trial):study rationale and design. BMC Endocrine Disorders 2012;12:10
14. The guidelines manual 2012. UK National Institute for Health and Clinical Excellence, 2012. Available at:www.nice.org.uk/article/PMG6/chapter/7-Assessing-cost-effectiveness [Last accessed 27 August 2015]
15. M.Evans, K.Khunti, M.Mamdani,. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events:a time trade-off survey in five countries. Health Qual Life Outcomes 2013;11:90
16. R.M.Agesen, P.L.Kristensen, H.Beck-Nielsen,. Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes proneto severe hypoglycaemia:the HypoAna trial. Diabetes Metab 2016 April 7; doi:10.1016/j.diabet.2016.03.001
17. C.J.Currie, C.D.Poole, A.Woehl,. The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy. Diabetologia 2006;49:2272-80
18. M.Monami, N.Marchionni, E.Mannucci Long-acting insulin analogues vs NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009;11:372-8
19. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes:effects of treatment modalities and their duration. Diabetologia 2007;50:1140-7
20. L.A.Donnelly, A.D.Morris, B.M.Frier,.; DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes:a population-based study. Diabet Med 2005;22:749-55
21. K.Khunti, R.Alsifri, M.Aronson,. Self-reported hypoglycaemia:a global study of 24 countries with 27,585 insulin-treated patients with diabetes:the HAT study. Diabetes Res Clin Pract 2014;106:S105-S6
22. J.Chancellor, S.Alballéa, A.Lawrence,. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics 2008;26:217-34
23. A.R.Levy, T.L.Christensen, J.A.Johnson Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008;6:73
24. S.Harris, M.Mamdani, C.B.Galbo-Jørgensen,. The effect of hypoglycemia on health-related quality of life:Canadian results from a multinational time trade-off survey. Can J Diabetes 2014;38:45-52
25. M.Evans, M.Wolden, J.Gundgaard,. Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK. J Med Econ 2015;18:56-68
26. C.J.Currie, C.L.Morgan, C.D.Poole,. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523-34
27. S.R.Heller, B.M.Frier, M.L.Hersløv,. Severe hypoglycaemia in adults with insulin-treated diabetes:impact on healthcare resources. Diabet Med 2016;33:471-7
28. M.Brod, T.Christensen, T.L.Thomsen, D.M.Bushnell The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
29. W.J.Valentine, J.Jendle, M.Saraheimo,. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabet Med 2012;29:303-12
30. W.J.Valentine, M.Aagren, M.Haglund,. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal–bolus regimen in Sweden. Scand J Public Health 2011;39:79-87
31. M.H.Gschwend, M.Aagren, W.J.Valentine Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal–bolus regimen in five European countries. J Med Econ 2009;12:114-23